Reduced-dose WBRT combined with SRS for 1-4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control.
Nakano T, Aoyama H, Onodera S, Igaki H, Matsumoto Y, Kanemoto A, Shimamoto S, Matsuo M, Tanaka H, Oya N, Matsuyama T, Ohta A, Maruyama K, Tanaka T, Kitamura N, Akazawa K, Maebayashi K; Japanese Radiation Oncology Study Group 13-1 (JROSG13-1) Investigators.
Nakano T, et al. Among authors: onodera s.
Clin Transl Radiat Oncol. 2022 Sep 27;37:116-129. doi: 10.1016/j.ctro.2022.09.005. eCollection 2022 Nov.
Clin Transl Radiat Oncol. 2022.
PMID: 36199814
Free PMC article.